Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIK, Hydrocortisone and Sevelamer in Acute Aluminum Phosphide Poisoning
NCT07451561Not yet recruiting
- Sponsor
- Sohag University
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Trial of glucose-insulin-potassium, hydrocortisone and sevelamer carbonate in aluminum phosphide poisoning (2 arms), sponsored by Sohag University. Primary endpoint: Change in mortality rate at 1 year. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
glucose-insulin-potassiumhydrocortisonesevelamer carbonate
03
Conditions
aluminum phosphide poisoning
Beyond the preview
Go deeper on NCT07451561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07451561.